Therapy combining dinutuximab with granulocyte macrophage colony stimulating factor, interleukin 2, and isotretinoin has significant side effects; however, these complications are generally predictable and can be managed proactively.
BalunaR. G. (2007). Cytokine-induced vascular leak syndrome, cytokines in human health. In HouseR. V.DescotesJ. (Eds.), Immunotoxicology, pathology and therapeutic applications (pp. 205-231). Totowa, NJ: Humana Press.
2.
BrodeurG. M. (2003). Neuroblastoma: Biological insights into a clinical enigma. Nature Reviews, Cancer, 3, 203-216.
3.
ChameidesL.SamsonR. A.SchexnayderS. M.HazinskiM. F. (2011). Pediatric advanced life support: Providers manual. Dallas, TX: American Heart Association.
4.
DescotesJ. (2009). Immunotoxicity of monoclonal antibodies. mAbs, 1(2), 104-111.
5.
GillinS.SorkinL. S. (1998). Gabapentin reverses the allodynia produced by the administration of anti-GD2 ganglioside, an immunotherapeutic drug. Anesthesia & Analgesia, 86, 111-116.
6.
HowladerN.NooneA. M.KrapchoM.NeymanN.AminouR.WaldronW.. . . CroninK. A. (Eds.). (2012). SEER cancer statistics review, 1975-2009 (Vintage 2009 populations). Bethesda, MD: National Cancer Institute. Retrieved from http://seer.cancer.gov/csr/1975_2009_pops09/
7.
KremensB.HeroB.EsserJ.WeinelP.Filger-BrillingerJ.FleischhackG.. . . BertholdF. (2002). Ocular symptoms in children treated with human-mouse chimeric anti-GD2 mAb ch14.18 for neuroblastoma. Cancer Immunology, Immunotherapy, 51, 107-110.
8.
MatthayK.ReynoldsC.SeegerR.ShimadaH.AdkinsE.GerbingR.. . . VillablancaJ. (2009). Long-term results for children with high-risk neuroblastoma treated on randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children’s Oncology Group study. Journal of Clinical Oncology, 27, 1007-1013.
9.
OzkaynakF.GilmanA. L.YuA. L.LondonW. B.SondelP. M.SmithM.. . . ParkJ. R (2014, June). A comprehensive safety trial of chimeric antibody (ch14.18) with GN-CSF, IL-2 and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children’s Oncology Group study. Posterpresented at the American Society of Clinical Oncology annual meeting, Chicago, IL.
10.
ParsonsK.BerndardtB.StricklandB. (2013). Targeted immunotherapy for high-risk neuroblastoma: The role of monoclonal antibodies. Annals of Pharmacotherapy, 47, 210-218.
11.
SchulzG.ChereshD. A.VarkiN. M.YuA.StaffilenoL. K.ReisfeldR. A. (1984). Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Research, 44, 5914-5920.
12.
SchwartzR.StoverL.DutcherJ. (2002). Managing toxicities of high-dose interleukin-2. Oncology, 16, 11-20.
13.
SiegelJ. P.PuriR. K. (1991). Interleukin-2 toxicity. Journal of Clinical Oncology, 9, 694-704.
YuA. L.GilmanA. L.OzkaynakM. F.LondonW. B.KreissmanS. G.ChenH. X.SondelP. M. (2010). Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. New England Journal of Medicine, 363, 1324-1334.
